Venlo
VENLO, The Netherlands, October 7, 2011 -
QIAGEN N.V.
VENLO, the Netherlands, June 15, 2011 -
QIAGEN in exclusive negotiations
to purchase 47% initial
stake in Ipsogen S.A.and
then fully acquire a global leader
in hematologic (blood) cancer molecular
diagnostics
Ipsogen has a competitive portfolio
in blood cancer testing with assays
covering 15 biomarkers-including BCR-ABL and
JAK2 -for patient profiling and
monitoring
Many of Ipsogen's assays have
significant potential as companion diagnostics to
help select and guide treatment decisions in
personalized healthcare
Addition of Ipsogen would
strengthen QIAGEN's leadership in
molecular diagnostics, significantly expanding
its profiling and personalized
healthcare portfolios
QIAGEN N.V.
VENLO, Netherlands and MELBOURNE, Australia, April 3, 2011 - -- QIAGEN to acquire Cellestis Limited (CST:AU) via a Scheme of
Arrangement (the Scheme) for approximately A$341 million(1) (US$355 million),
or A$3.55 per share
-- Unanimous support from Cellestis board of directors(2); QIAGEN granted
options to acquire up to 19.9% of Cellestis ordinary shares under certain
circumstances, subject to regulatory approvals
-- Acquisition provides QIAGEN with exclusive access to QuantiFERON(R)
technology for high sensitivity, early disease detection not possible with
other diagnostic approaches
-- QuantiFERON(R) technology successfully commercialized with two
marketed Cellestis tests for detection of latent tuberculosis (TB) and
life-threatening CMV virus
-- QIAGEN to expand QuantiFERON(R) portfolio, migrate technology to
QIAsymphony and QIAensemble platforms and leverage synergies with current
QIAGEN assay portfolio and pipeline
-- Acquisition would accelerate QIAGEN's sales and adjusted EPS growth
rates in 2012
QIAGEN N.V.
VENLO, The Netherlands, September 1, 2010 - QIAGEN N.V.
VENLO, The Netherlands, February 8 - QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today
announced that its wholly owned subsidiary DxS has acquired the global and
exclusive licence for biomarker PI3K from Johns Hopkins University to develop
real-time-PCR and endpoint PCR assays.
